MarketCap
Facebook
X
Telegram
CEL-SCI Corporation EBITDA | CVM
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA CEL-SCI Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -22.8 M | -24.2 M | -29.4 M | -34.1 M | -35.7 M | -28.1 M | -19.6 M | -16.1 M | -20.7 M | -25.4 M | -34.1 M | -27.3 M | -19.5 M | -16.7 M | -17.5 M | -18 M | -11.6 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -11.6 M | -35.7 M | -23.6 M |
Quarterly EBITDA CEL-SCI Corporation
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.41 M | -4.4 M | -4.4 M | - | -5.48 M | -6.39 M | -5.9 M | - | -6.66 M | -7.07 M | -5.48 M | - | -8.17 M | -8.17 M | -6.66 M | -24.3 M | -8.71 M | -9.54 M | -7.96 M | -26.1 M | -10.4 M | -8.52 M | -8.18 M | -18.9 M | -5.9 M | -8.18 M | -6.35 M | -4.7 M | -4.89 M | -6.35 M | -4.88 M | -12.8 M | -3.78 M | -4.88 M | -4.77 M | -17.1 M | -4.44 M | -4.76 M | -4.78 M | -5.88 M | -5.57 M | -4.78 M | -5.14 M | -25.8 M | -8.15 M | -5.74 M | -9.94 M | -18.9 M | -6.84 M | -9.94 M | -5.88 M | -14.5 M | -5.43 M | -5.88 M | -4.91 M | -12.5 M | -4.1 M | -4.91 M | -4.3 M | -13.9 M | -4.72 M | -4.3 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -3.41 M | -26.1 M | -8.23 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Tarsus Pharmaceuticals
TARS
|
-70.1 M | $ 73.9 | 4.32 % | $ 3.09 B |  USA |
 |
Bio-Techne Corporation
TECH
|
349 M | $ 72.83 | -0.01 % | $ 11.4 B | USA |
 |
Sage Therapeutics
SAGE
|
-431 M | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
49.8 M | - | - | $ 1.62 B |  Israel |
 |
Cabaletta Bio
CABA
|
-171 M | $ 1.43 | -5.0 % | $ 144 M | USA |
 |
Forma Therapeutics Holdings
FMTX
|
-172 M | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
16.3 M | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
1.01 B | - | - | $ 26.6 B |  Irlanda |
 |
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-124 M | $ 4.12 | -8.35 % | $ 35.1 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
-45.7 M | - | - | $ 121 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-144 M | $ 11.55 | 4.52 % | $ 1.61 B |  France |
 |
Gilead Sciences
GILD
|
10.4 B | $ 170.68 | 0.8 % | $ 212 B | USA |
 |
Taysha Gene Therapies
TSHA
|
-109 M | $ 4.28 | -2.06 % | $ 1.37 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-43.7 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | USA |
 |
Unity Biotechnology
UBX
|
-30.3 M | - | -33.41 % | $ 3.37 M | USA |
 |
iTeos Therapeutics
ITOS
|
-158 M | - | - | $ 411 M | USA |
 |
Gossamer Bio
GOSS
|
-171 M | $ 11.2 | 5.21 % | $ 2.56 B | USA |
 |
GeoVax Labs
GOVX
|
-21.6 M | $ 0.11 | -22.17 % | $ 105 K | USA |
 |
United Therapeutics Corporation
UTHR
|
1.58 B | $ 588.33 | 1.01 % | $ 26.1 B | USA |
 |
Seelos Therapeutics
SEEL
|
-40.5 M | - | -47.76 % | $ 6.27 M | USA |
 |
Vericel Corporation
VCEL
|
22.6 M | $ 59.02 | 1.08 % | $ 2.97 B | USA |
 |
Veracyte
VCYT
|
79.2 M | $ 24.05 | -7.21 % | $ 1.89 B | USA |
 |
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | USA |
 |
GlaxoSmithKline plc
GSK
|
7.93 B | $ 51.25 | -0.56 % | $ 208 B |  Britain |
 |
Vir Biotechnology
VIR
|
-468 M | $ 13.17 | -3.48 % | $ 1.82 B | USA |
 |
Viking Therapeutics
VKTX
|
-393 M | $ 28.67 | -1.1 % | $ 3.23 B | USA |
 |
Vanda Pharmaceuticals
VNDA
|
-150 M | $ 4.07 | -0.49 % | $ 240 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
-12.1 M | $ 3.55 | -1.11 % | $ 37.8 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
4.38 B | $ 547.74 | -0.57 % | $ 140 B | USA |
 |
Kiromic BioPharma
KRBP
|
-21.5 M | - | 6.61 % | $ 3.08 M | USA |
 |
vTv Therapeutics
VTVT
|
-32.8 M | $ 20.88 | -1.42 % | $ 83.8 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-16 M | $ 3.81 | -3.3 % | $ 1.69 M | USA |
 |
Voyager Therapeutics
VYGR
|
-128 M | $ 1.82 | -8.54 % | $ 107 M | USA |
 |
Calithera Biosciences
CALA
|
-41.8 M | - | -10.95 % | $ 876 K | USA |
 |
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | USA |
 |
Wave Life Sciences Ltd.
WVE
|
-212 M | $ 3.41 | -2.01 % | $ 575 M | Singapore |
 |
Molecular Templates
MTEM
|
-3.82 M | - | -23.43 % | $ 495 K | USA |
 |
Exicure
XCUR
|
-3.99 M | $ 1.08 | 21.31 % | $ 6.8 M | USA |
 |
Immunome
IMNM
|
-222 M | $ 18.65 | -3.67 % | $ 1.63 B | USA |
 |
Xeris Pharmaceuticals
XERS
|
26.2 M | $ 15.81 | -0.35 % | $ 2.54 B | USA |
 |
X4 Pharmaceuticals
XFOR
|
-85.6 M | $ 3.24 | -2.7 % | $ 137 M | USA |
 |
Xencor
XNCR
|
-167 M | $ 39.42 | 2.16 % | $ 2.93 B | USA |
 |
INmune Bio
INMB
|
-47.3 M | $ 1.09 | -3.54 % | $ 27 M | USA |
 |
Insmed Incorporated
INSM
|
-1.24 B | $ 119.55 | 2.97 % | $ 23.8 B | USA |
 |
Ionis Pharmaceuticals
IONS
|
-204 M | $ 28.02 | -9.63 % | $ 4.48 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-50.2 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
InflaRx N.V.
IFRX
|
-44.9 M | $ 1.21 | -7.63 % | $ 81.4 M |  Germany |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
-2.17 M | $ 1.78 | 16.33 % | $ 1.2 B | Israel |
 |
22nd Century Group
XXII
|
-11.1 M | $ 1.46 | -10.43 % | $ 269 K | USA |